Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
about
Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's PerspectiveIL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates.JNK1 controls mast cell degranulation and IL-1{beta} production in inflammatory arthritisProbiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells.Inhibition of inflammatory arthritis using fullerene nanomaterials.Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammationIL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling.Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis.A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activationMast cell regulation of the immune response.Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation.Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a studyA proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.Tyrosine kinases as targets for the treatment of rheumatoid arthritis.Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?The role of leukotrienes in immunopathogenesis of rheumatoid arthritis.Cellular sources of IL-17 in psoriasis: a paradigm shift?Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review.Degenerative Joint Diseases and Neuroinflammation.[Chronic pruritus in autoimmune dermatoses : results of a comparative survey].The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice.Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1.Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies.An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouse.Study of the role of "gatekeeper" mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/docking approach.A20-deficient mast cells exacerbate inflammatory responses in vivo.The protective effects of ultraviolet A1 irradiation on spontaneous lupus erythematosus-like skin lesions in MRL/lpr miceMore about masitinib.Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed.In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
P2860
Q26775911-B42A9878-CB8A-46C0-B04E-C2551A47DEF0Q34009808-DDE36CFD-E69D-4250-82D3-7D607596A077Q34438110-87256660-5AED-4A79-B64E-89B707FB1539Q34591182-4E56A83E-CE05-422B-BBBB-778429A007B8Q35448218-6CDED4CF-31B9-4CF0-983D-0D918573D9FFQ35557372-CF57E5F9-9BDE-4DE4-AF09-E759830F31D6Q35787352-47ABBEF1-8D26-4B04-9742-99A62B8520FAQ35840765-236D8BC1-8548-41B4-93A7-B14AB29CB214Q36084902-C0893FAA-179C-47A8-B457-F5CF6A108389Q36834357-37D347EE-B769-4FBF-B284-5F9765C4B0E0Q37143569-579FD97E-F006-4F78-B377-7ADC1134E0C9Q37270882-54738D85-3189-40CD-8A9A-EE79A5071522Q37369583-201F0F6B-BAF7-4A57-889D-E4AD2974EA51Q37506087-29CAB6F3-8DFA-4EC4-9894-7EB411F59AF2Q38045474-0DEBAA22-C98A-49CD-9BDB-173BB28908D8Q38193193-DE04CC55-26C2-4B7E-B7C8-376D2665055CQ38231403-B33F53DD-4F0A-493A-8683-98DE2ABD8444Q38923398-1DC13A78-77A0-43E7-AD5D-5073F49FDB73Q39063573-1399353E-AEBF-4BBA-A4C9-EA518481781BQ39245866-87650C34-0B71-4BD2-9A32-3270C3D23729Q39253354-B4B69F34-E9BE-4C98-BDA3-F4103F2B5298Q40417890-E9679265-A59E-4801-B68D-0C4C987E0CC6Q41121882-96724291-E4D1-4301-816F-9F02D9C3FD3DQ41134791-4475B1A2-FABF-4C85-8510-AE24B0910843Q41161520-920F956D-3BD8-47FC-9C2C-31FE6B982203Q41871362-E1B90533-EDD0-4C00-902E-86AD86DDF199Q42121993-CE273410-9B34-48B6-AB6E-44A4E18BDCEEQ42558320-02091B8F-A7E7-47E4-BE32-2DCB27C8142FQ53668242-04A12CFC-23B7-4080-A616-58E630ABA591Q53815614-18E25E5D-8DD5-4903-9FD5-C8E4BFAFC47BQ54544974-AB21217D-F7C5-446B-82C7-FBD4BC20C7C9
P2860
Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mast cells in the pathogenesis ...... ts for anti-rheumatic therapy.
@en
type
label
Mast cells in the pathogenesis ...... ts for anti-rheumatic therapy.
@en
prefLabel
Mast cells in the pathogenesis ...... ts for anti-rheumatic therapy.
@en
P2860
P1476
Mast cells in the pathogenesis ...... ts for anti-rheumatic therapy.
@en
P2093
Kari K Eklund
P2860
P356
10.1111/J.1600-065X.2007.00504.X
P577
2007-06-01T00:00:00Z